Skip to main content
Addgene
Open Menu

Enter a sequence to perform a BLAST-based search of Addgene plasmid sequence databases.

Information

In Category

Filter By

We narrowed to 1,067 results for: RHOD;

Showing: 961 - 980 of 1067 results

  1. SARS-CoV-2 Spike (S) Receptor Binding Domain (RBD) library E484K Tile 1 (positions 333-436)

    Pooled Library
    #174293
    Purpose
    This library contains mutations to SARS-CoV-2 Spike RBD E484K variant in which all surface exposed residues on S RBD (Tile 1, positions 333-436) were mutated to every other amino acid.
    Depositor
    Timothy Whitehead
    Article
    Francino-Urdaniz et al Cell Rep. 2021 Aug 31;36(9):109627. doi:
    Expression
    Yeast
    Available Since
    Sept. 13, 2021
    Availability
    Academic Institutions and Nonprofits only

  2. pAAV_hSyn_WiChR_TS_mScarlet_ER (AAV9)

    Viral Prep
    #205997-AAV9
    Purpose
    Ready-to-use AAV9 particles produced from pAAV_hSyn_WiChR_TS_mScarlet_ER (#205997). In addition to the viral particles, you will also receive purified pAAV_hSyn_WiChR_TS_mScarlet_ER plasmid DNA. hSyn-driven K+ selective channelrhodopsin for optogenetic inhibition of neurons. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Peter Hegemann, Johannes Vierock
    Article
    Vierock et al Sci Adv. 2022 Nov 16:eadd7729.
    Promoter
    Syn
    Tags
    mScarlet
    Available Since
    July 30, 2025
    Availability
    Academic Institutions and Nonprofits only

  3. pAAV_hSyn1-SIO-stGtACR1-FusionRed (AAV5)

    Viral Prep
    #105678-AAV5
    Purpose
    Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR1-FusionRed (#105678). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR1-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Ofer Yizhar
    Article
    Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1
    Promoter
    Syn
    Tags
    FusionRed (Cre-dependent)
    Available Since
    Sept. 24, 2020
    Availability
    Academic Institutions and Nonprofits only

  4. pAAV_hSyn1-SIO-stGtACR2-FusionRed (AAV1)

    Viral Prep
    #105677-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Ofer Yizhar
    Article
    Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1
    Promoter
    Syn
    Tags
    FusionRed (Cre-dependent)
    Available Since
    Aug. 17, 2018
    Availability
    Academic Institutions and Nonprofits only

  5. pAAV-CKIIa-stGtACR2-FusionRed (AAV1)

    Viral Prep
    #105669-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Ofer Yizhar
    Article
    Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1
    Promoter
    CaMKII
    Tags
    FusionRed
    Available Since
    July 17, 2018
    Availability
    Academic Institutions and Nonprofits only

  6. pAAV_hSyn1-SIO-stGtACR2-FusionRed (AAV5)

    Viral Prep
    #105677-AAV5
    Purpose
    Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Ofer Yizhar
    Article
    Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1
    Promoter
    Syn
    Tags
    FusionRed (Cre-dependent)
    Available Since
    Oct. 21, 2024
    Availability
    Academic Institutions and Nonprofits only

  7. pAAV_hSyn1-SIO-stGtACR2-FusionRed (AAV Retrograde)

    Viral Prep
    #105677-AAVrg
    Purpose
    Ready-to-use AAV Retrograde particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Ofer Yizhar
    Article
    Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1
    Promoter
    Syn
    Tags
    FusionRed (Cre-dependent)
    Available Since
    July 8, 2020
    Availability
    Academic Institutions and Nonprofits only

  8. pAAV-CKIIa-stGtACR2-FusionRed (AAV Retrograde)

    Viral Prep
    #105669-AAVrg
    Purpose
    Ready-to-use AAV Retrograde particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Ofer Yizhar
    Article
    Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1
    Promoter
    CaMKII
    Tags
    FusionRed
    Available Since
    July 8, 2020
    Availability
    Academic Institutions and Nonprofits only

  9. pAAV-double floxed-eNpHR-EYFP-WPRE-pA (AAV9)

    Viral Prep
    #20949-AAV9
    Purpose
    Ready-to-use AAV9 particles produced from pAAV-double floxed-eNpHR-EYFP-WPRE-pA (#20949). In addition to the viral particles, you will also receive purified pAAV-double floxed-eNpHR-EYFP-WPRE-pA plasmid DNA. EF1a-driven, cre-dependent eNpHR EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Promoter
    EF1a
    Tags
    EYFP (Cre-dependent)
    Available Since
    July 12, 2018
    Availability
    Academic Institutions and Nonprofits only

  10. pACAGW-ChR2-Venus-AAV (AAV1)

    Viral Prep
    #20071-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pACAGW-ChR2-Venus-AAV (#20071). In addition to the viral particles, you will also receive purified pACAGW-ChR2-Venus-AAV plasmid DNA. CAG-driven, channelrhodopsin fused to Venus for optogenetic activation. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karel Svoboda
    Article
    Leopoldo et al Nature. 2009 Jan 18.
    Promoter
    CAGG
    Tags
    Venus
    Available Since
    Feb. 21, 2018
    Availability
    Academic Institutions and Nonprofits only

  11. pACAGW-ChR2-Venus-AAV (AAV9)

    Viral Prep
    #20071-AAV9
    Purpose
    Ready-to-use AAV9 particles produced from pACAGW-ChR2-Venus-AAV (#20071). In addition to the viral particles, you will also receive purified pACAGW-ChR2-Venus-AAV plasmid DNA. CAG-driven, channelrhodopsin fused to Venus for optogenetic activation. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karel Svoboda
    Article
    Leopoldo et al Nature. 2009 Jan 18.
    Promoter
    CAGG
    Tags
    Venus
    Available Since
    March 15, 2018
    Availability
    Academic Institutions and Nonprofits only

  12. pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE (AAV1)

    Viral Prep
    #125713-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE (#125713). In addition to the viral particles, you will also receive purified pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Ofer Yizhar
    Article
    Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)
    Promoter
    Syn
    Tags
    mScarlet (Cre-dependent)
    Available Since
    Sept. 20, 2019
    Availability
    Academic Institutions and Nonprofits only

  13. pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (AAV5)

    Viral Prep
    #125712-AAV5
    Purpose
    Ready-to-use AAV5 particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Ofer Yizhar
    Article
    Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)
    Promoter
    short version of αCamKinase II promoter (0.4kb)
    Tags
    mScarlet
    Available Since
    June 26, 2024
    Availability
    Academic Institutions and Nonprofits only

  14. pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE (AAV5)

    Viral Prep
    #125713-AAV5
    Purpose
    Ready-to-use AAV5 particles produced from pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE (#125713). In addition to the viral particles, you will also receive purified pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Ofer Yizhar
    Article
    Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)
    Promoter
    Syn
    Tags
    mScarlet (Cre-dependent)
    Available Since
    Sept. 13, 2021
    Availability
    Academic Institutions and Nonprofits only

  15. pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (AAV1)

    Viral Prep
    #125712-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Ofer Yizhar
    Article
    Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)
    Promoter
    short version of αCamKinase II promoter (0.4kb)
    Tags
    mScarlet
    Available Since
    June 26, 2024
    Availability
    Academic Institutions and Nonprofits only

  16. pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (AAV Retrograde)

    Viral Prep
    #125712-AAVrg
    Purpose
    Ready-to-use AAV Retrograde particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Ofer Yizhar
    Article
    Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)
    Promoter
    short version of αCamKinase II promoter (0.4kb)
    Available Since
    Jan. 8, 2025
    Availability
    Academic Institutions and Nonprofits only

  17. pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 (AAV5)

    Viral Prep
    #100054-AAV5
    Purpose
    Ready-to-use AAV5 particles produced from pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 (#100054). In addition to the viral particles, you will also receive purified pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 plasmid DNA. CAG-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Promoter
    CAG
    Tags
    mCherry
    Available Since
    Feb. 15, 2018
    Availability
    Academic Institutions and Nonprofits only

  18. pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 (AAV9)

    Viral Prep
    #100054-AAV9
    Purpose
    Ready-to-use AAV9 particles produced from pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 (#100054). In addition to the viral particles, you will also receive purified pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 plasmid DNA. CAG-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Promoter
    CAG
    Tags
    mCherry
    Available Since
    Feb. 14, 2018
    Availability
    Academic Institutions and Nonprofits only

  19. pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 (AAV1)

    Viral Prep
    #100054-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 (#100054). In addition to the viral particles, you will also receive purified pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 plasmid DNA. CAG-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Promoter
    CAG
    Tags
    mCherry
    Available Since
    March 7, 2018
    Availability
    Academic Institutions and Nonprofits only

  20. pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 (AAV2)

    Viral Prep
    #100054-AAV2
    Purpose
    Ready-to-use AAV2 particles produced from pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 (#100054). In addition to the viral particles, you will also receive purified pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 plasmid DNA. CAG-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Promoter
    CAG
    Tags
    mCherry
    Available Since
    Oct. 7, 2020
    Availability
    Academic Institutions and Nonprofits only
Showing: 961 - 980 of 1067 results